ArticleNature2021
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 988 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
988citing papers in PubMed, 1 pooled it
93.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
988 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,499 citations in OpenAlex.
- Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis.Viruses · 2023Pooled it
- SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback.The Journal of infectious diseases · 2024Trial
- The advances and challenges of mRNA-LNP application in fields of hematology and oncology therapeutics.Journal of hematology & oncology · 2026Review
- R1-32-like public antibodies acquire tolerance to SARS-CoV-2 antigenic drift through somatic hypermutation.PLoS biology · 2026Article
- Environmental drivers of low vaccine responsiveness in a lab-to-wild rodent model.PLoS pathogens · 2026Article
- Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid.PLoS pathogens · 2026Article
- A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization.bioRxiv : the preprint server for biology · 2026Article
- Safety and efficacy of COVID-19 vaccines in pregnant and lactating women: a comprehensive review.Inflammopharmacology · 2026Review
- Utilizing virus genomic surveillance to predict vaccine effectiveness.PLoS computational biology · 2026Article
- Impact of timely vaccination and genomic surveillance on controlling consecutive waves of SARS-CoV-2 variants.Scientific reports · 2026Article
- Peripheral vaccination-induced brain-resident memory CD8+ T cells durably protect mice against intracranial malignancy.The Journal of clinical investigation · 2026Article
- Mechanisms underlying immunodynamics of layered defenses elicited by mRNA vaccination in children.BMC medicine · 2026Article
- Immunological memory to vaccines.Immunity · 2026Review
- AI-aided engineering and production optimization of chimeric hetero-viral capping enzymes for mRNA vaccines.Scientific reports · 2026Article
- STING agonists as antiviral agents.FEBS letters · 2026Review
- Self-amplifying COVID-19 mRNA vaccination induces longitudinally enhanced antibody function in a Phase 3 trial.NPJ vaccines · 2026Article
- Design and immunogenicity evaluation of pan-recombinant vaccines based on the consensus sequence of severe acute respiratory syndrome coronavirus-2 spike protein.Scientific reports · 2026Article
- DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases.Nature biomedical engineering · 2026Article
- Antibody-antigen neutralization prediction by integrating structural information distillation and physicochemical constraints.Briefings in bioinformatics · 2026Article
- mRNA vaccination overcomes haemozoin-mediated impairment of whole-parasite malaria vaccines in mice.Nature microbiology · 2026Article
928 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Update of
Authors and funding
34 authors at 6 institutions in 1 country.
Zijun Wang *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Fabian Schmidt *Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Yiska Weisblum *Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Frauke Muecksch *Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-0132-5101
Christopher O Barnes *Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Shlomo Finkin *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-4474-2658
Dennis Schaefer-Babajew *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-5380-2950
Melissa Cipolla *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Christian Gaebler *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-7295-8128
Jenna A Lieberman *Lymphocyte Nuclear Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Thiago Y OliveiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-2654-0879
Zhi YangDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Morgan E AbernathyDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Kathryn E Huey-TubmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Arlene HurleyHospital Program Direction, The Rockefeller University, New York, NY, USA.
Martina TurrojaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-9640-0559
Kamille A WestDepartment of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Kristie GordonLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Katrina G MillardLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-2247-3178
Victor RamosLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-7353-3420
Justin Da SilvaLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-6393-0000
Jianliang XuLymphocyte Nuclear Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-4154-4322
Robert A ColbertPediatric Translational Research Branch and Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Roshni PatelLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Juan DizonLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Cecille Unson-O'BrienLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Irina ShimeliovichLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Anna GazumyanLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-1727-8693
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA. bjorkman@caltech.edu.ORCID http://orcid.org/0000-0002-2277-3990
Rafael CasellasLymphocyte Nuclear Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA. rafael.casellas@nih.gov.ORCID http://orcid.org/0000-0001-9282-2287
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA. thatziio@rockefeller.edu.ORCID http://orcid.org/0000-0002-7889-0766
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu.ORCID http://orcid.org/0000-0002-2368-3719
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. nussen@rockefeller.edu.ORCID http://orcid.org/0000-0003-0592-8564
Rockefeller University · USCalifornia Institute of Technology · USNational Institutes of Health · USHoward Hughes Medical Institute · USNational Institutes of Health Clinical Center · USRockefeller University Hospital · US
Funding
Pathogenic Mechanisms in SpondyloarthritisZIAAR041184 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI COLBERT, ROBERT · 2009 to 2025
$47.6MDeveloping, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MUnderstanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI RAVETCH, JEFFREY VICTOR · 2014 to 2023
$26.0MVirus TransmissionP50AI150464 · NIAID · UNIVERSITY OF UTAH · PI HOPE, THOMAS · 2019 to 2021
$14.9MOvercoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS.R01AI078788 · NIAID · ROCKEFELLER UNIVERSITY · PI HATZIIOANNOU, THEODORA · 2008 to 2021
$9.3MVirology CoreP01AI138938 · NIAID · ROCKEFELLER UNIVERSITY · PI BJORKMAN, PAMELA J · 2018 to 2022
$8.4MDiscovery and Mechanism of Antiretroviral FactorsR37AI064003 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2011 to 2020
$4.9MDevelopment of highly neutralizing nanobodies against HIV-1, SARS-CoV-2 and other pathogensZIAAR041211 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI O'SHEA, JOHN · 2020 to 2023
$2.5MHoward Hughes Medical InstituteNCATS NIH HHS UL1 TR001866NIAID NIH HHS P01 AI138938NIAID NIH HHS P50 AI150464NIAID NIH HHS R01 AI078788NIAID NIH HHS R37 AI064003NIAID NIH HHS U19 AI111825NIH HHS 2U19AI111825NIH HHS P01 AI138398-S1NIH HHS P50 AI150464-13NIH HHS R01 AI78788Wellcome Trust
Abstract
Here we report on the antibody and memory B cell responses of a cohort of 20 volunteers who received the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccine against SARS-CoV-2
Indexed as
2019-nCoV Vaccine mRNA-1273AdultAgedAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralB-LymphocytesBNT162 VaccineCOVID-19COVID-19 VaccinesCryoelectron MicroscopyEpitopes, B-LymphocyteFemaleHumansImmunization, SecondaryImmunoglobulin G2019-nCoV Vaccine mRNA-1273Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesEpitopes, B-LymphocyteImmunoglobulin GImmunoglobulin MmRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Synthetic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.